Low Use of Statins among High-risk Patients in China

Low Use of Statins among High-risk Patients in China

Bibliográfalaš dieđut
Váldodahkkit:	Jiang, L, Armitage, J, Chen, Y, Landray, M, Li, J, Feng, F, Liu, J, Gao, Y, Zhang, D, Zhang, H
Materiálatiipa:	Conference item
Almmustuhtton:	2010

Geahča maid

Underuse of statins in patients with atherosclerotic ischemic stroke in China.
Dahkki: Li, X, et al.
Almmustuhtton: (2012)

[ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study].
Dahkki: Liu, J, et al.
Almmustuhtton: (2013)

Risk Factor Control among Chinese High-Risk Patients with Diabetes
Dahkki: Chen, F, et al.
Almmustuhtton: (2010)

The safety of statins in clinical practice.
Dahkki: Armitage, J
Almmustuhtton: (2007)

[A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China.]
Dahkki: Jiang, L, et al.
Almmustuhtton: (2010)

Cardiovascular outcomes among participants with diabetes in the recent large statin trials.
Dahkki: Armitage, J, et al.
Almmustuhtton: (2004)

Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
Dahkki: Landray, M, et al.
Almmustuhtton: (2014)

Misrepresentation of statin safety evidence.
Dahkki: Armitage, J, et al.
Almmustuhtton: (2014)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
Dahkki: Hopewell, J, et al.
Almmustuhtton: (2009)

Niacin for reduction of cardiovascular risk.
Dahkki: Landray, M, et al.
Almmustuhtton: (2014)

Niacin for reduction of cardiovascular risk.
Dahkki: Landray, M, et al.
Almmustuhtton: (2014)

Statins for people at low risk of cardiovascular disease reply
Dahkki: Mihaylova, B, et al.
Almmustuhtton: (2012)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Dahkki: Mangravite, L, et al.
Almmustuhtton: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
Dahkki: Mangravite, L, et al.
Almmustuhtton: (2013)

Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Dahkki: Li, J, et al.
Almmustuhtton: (2012)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
Dahkki: Hopewell, J, et al.
Almmustuhtton: (2011)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
Dahkki: Hopewell, J, et al.
Almmustuhtton: (2014)

Lessons from the controversy over statins - Authors' reply.
Dahkki: Armitage, J, et al.
Almmustuhtton: (2016)

Does the benefit from statin therapy extend beyond 5 years?
Dahkki: Bulbulia, R, et al.
Almmustuhtton: (2013)

Does the benefit from statin therapy extend beyond 5 years?
Dahkki: Bulbulia, R, et al.
Almmustuhtton: (2013)

Safety and efficacy of statins - Authors' reply
Dahkki: Collins, R, et al.
Almmustuhtton: (2017)

Increased risk of diabetes with statin use: Reconsidering the use of high potency statins
Dahkki: Asfandyar Khan Niazi
Almmustuhtton: (2014-01-01)

Dementia and statins.
Dahkki: Ebrahim, S, et al.
Almmustuhtton: (2001)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Dahkki: Mihaylova, B, et al.
Almmustuhtton: (2009)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
Dahkki: Hopewell, J, et al.
Almmustuhtton: (2011)

Use of statins and risk of fractures.
Dahkki: van Staa, T, et al.
Almmustuhtton: (2000)

The Role of Combined Inflammatory Biomarkers in the Diagnosis of High- and Low-Virulence FRI Among High-Risk Lower Extremity Fractures
Dahkki: Xu X, et al.
Almmustuhtton: (2023-08-01)

Physical Activity Self-Efficacy Among Pregnant Women at High Risk for Gestational Diabetes Mellitus in China: A Cross-Sectional Study
Dahkki: Yang X, et al.
Almmustuhtton: (2024-12-01)

Effects of extended-release niacin with laropiprant in high-risk patients.
Dahkki: Landray, M, et al.
Almmustuhtton: (2014)

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Dahkki: Wu, R, et al.
Almmustuhtton: (2023)

The Impact of Statins before High-Risk CABG on Postoperative Multiple Organ Function
Dahkki: Jiayang Wang, et al.
Almmustuhtton: (2020-01-01)

Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Dahkki: Xiang‐Lin Tan, et al.
Almmustuhtton: (2020-04-01)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
Dahkki: Hopewell, J, et al.
Almmustuhtton: (2011)

Use of statins and risk of fractures.
Dahkki: van Staa, T, et al.
Almmustuhtton: (2001)

Statins and fracture risk - Reply
Dahkki: van Staa, T, et al.
Almmustuhtton: (2001)

Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.
Dahkki: Baigent, C, et al.
Almmustuhtton: (2004)

Statins and the risk of cataract
Dahkki: E. K. Butina, et al.
Almmustuhtton: (2019-12-01)

Reducing morbidity and mortality in high risk patients with statins
Dahkki: Vibhuti Singh, et al.
Almmustuhtton: (2009-06-01)

[Current statin use for patients with atherosclerotic cardiovascular disease in 39 large Chinese hospitals].
Dahkki: Zhang, D, et al.
Almmustuhtton: (2011)

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Dahkki: Sydney B Long, et al.
Almmustuhtton: (2010-12-01)